Efficacy, safety, and cost of Goeckerman therapy compared with biologics in the treatment of moderate to severe psoriasis

International Journal of Dermatology

Volumn 48, Issue 6, 2009, Pages 653-658

  De Miguel, Rebeca ^a   El azhary, Rokea ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEFACEPT; COAL TAR; EFALIZUMAB; ETANERCEPT; PSORALEN; RETINOID;

APPLICATION SITE BURNING; ARTICLE; COMPARATIVE STUDY; CONTACT DERMATITIS; COST BENEFIT ANALYSIS; DISEASE SEVERITY; GOECKERMAN METHOD; HUMAN; HYPERSENSITIVITY REACTION; PATIENT SAFETY; PHOTOTHERAPY; PSORIASIS; REMISSION; TREATMENT RESPONSE; ULTRAVIOLET A RADIATION; ULTRAVIOLET B RADIATION; WHOLE BODY RADIATION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL THERAPY; CHILD; COAL TAR; DATABASES, FACTUAL; DRUG COSTS; FEMALE; HEALTH CARE COSTS; HUMANS; KERATOLYTIC AGENTS; MALE; MIDDLE AGED; PSORIASIS; REMISSION INDUCTION; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; ULTRAVIOLET THERAPY; YOUNG ADULT;

EID: 66849106514     PISSN: 00119059     EISSN: 13654632     Source Type: Journal    
DOI: 10.1111/j.1365-4632.2009.04012.x     Document Type: Article

References (53)

1. Luba KM, Stulberg DL. Chronic plaque psoriasis. Am Fam Physician 2006; 73: 636-644.
2. Leon A, Nguyen A, Letsinger J, et al. An attempt to formulate an evidence-based strategy in the management of moderate-to-severe psoriasis: A review of the efficacy and safety of biologics and prebiologic options. Expert Opin Pharmacother 2007; 8: 617-632.
3. Rapp SR, Feldman SR, Exum ML, et al. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol 1999; 41: 401-407.
4. Goeckerman WH. Treatment of psoriasis. North West Med 1925; 24: 229-231.
5. Lee E, Koo J. Modern modified "ultra" Goeckerman therapy: A PASI assessment of a very effective therapy for psoriasis resistant to both pre-biologic and biologic therapies. J Dermatol Treat 2005; 16: 102-107.
6. Perry HO, Soderstrom CW, Schulze RW. The Goeckerman treatment of psoriasis. Arch Dermatol 1968; 98: 178-182.
7. Muller SA, Perry HO. The Goeckerman treatment in psoriasis: Six decades of experience at Mayo Clinic. Cutis 1984; 34: 265-270.
8. Lim HW, Anderson TF, Douglass M, et al. Cost-effectiveness of methotrexate and Goeckerman therapy: A flawed analysis. Arch Dermatol 1999; 135: 717-718.
9. Naldi L, Griffiths CE. Traditional therapies in the management of moderate to severe chronic plaque psoriasis: An assessment of the benefits and risks. Br J Dermatol 2005; 152: 597-615.
10. Schleyer V, Landthaler M, Szeimies RM. Novel pharmacological approaches in the treatment of psoriasis. J Eur Acad Dermatol Venereol 2005; 19: 1-20.
11. Graves JE, Nunley K, Heffernan MP. Off-label uses of biologics in dermatology. rituximab, omalizumab, infliximab, etanercept, adalimumab, efalizumab, and alefacept (part 2 of 2). J Am Acad Dermatol 2007; 56: e55-e79.
12. Langley RG, Gordon KB. Duration of remission of biologic agents for chronic plaque psoriasis. J Drugs Dermatol 2007; 6: 1205-1212.
13. Antoniou C, Stefanaki I, Stratigos A, et al. The Greek experience with efalizumab in psoriasis from a University Dermatologic Hospital. Br J Dermatol 2007; 156(Suppl. 2): 12-16.
14. Costanzo A, Peris K, Talamonti M, et al. Long-term treatment of plaque psoriasis with efalizumab: An Italian experience. Br J Dermatol 2007; 156(Suppl. 2): 17-23.
15. Ferrandiz C, Carrascosa JM. Managing moderate-to-severe psoriasis with efalizumab: Experience at a single Spanish institute. Br J Dermatol 2007; 156(Suppl. 2): 24-29.
16. Gladman DD, Mease PJ, Ritchlin CT, et al. Adalimumab for long-term treatment of psoriatic arthritis: Forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trial. Arthritis Rheum 2007; 56: 476-488.
17. Haitz KA, Kalb RE. Infliximab in the treatment of psoriasis in patients previously treated with etanercept. J Am Acad Dermatol 2007; 57: 120-125.
18. Paller AS, Siegfried EC, Langley RG, et al. Etanercept pediatric psoriasis study group. N Engl J Med 2008; 358: 241-251.
19. Kragballe K. Efalizumab in the treatment of chronic plaque psoriasis: experiences from the largest psoriasis treatment centre in Denmark. Br J Dermatol 2007; 156(Suppl. 2): 7-11.
20. Krueger GG, Elewski B, Papp K, et al. Patients with psoriasis respond to continuous open-label etanercept treatment after initial incomplete response in a randomized, placebo-controlled trial. J Am Acad Dermatol 2006; 54: S112-S119.
21. Menter A, Feldman SR, Weinstein GD, et al. A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1.year in the treatment of moderate-to-severe plaque psoriasis. J Am Acad Dermatol 2007; 56: 31.e1-31.e15.
22. Menter A, Tyring SK, Gordon K, et al. Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial. J Am Acad Dermatol 2008; 58: 106-115.
23. Papoutsaki M, Chimenti MS, Costanzo A, et al. Adalimumab for severe psoriasis and psoriatic arthritis: An open-label study in 30 patients previously treated with other biologics. J Am Acad Dermatol 2007; 57: 269-275.
24. Papp KA. The long-term efficacy and safety of new biological therapies for psoriasis. Arch Dermatol Res 2006; 298: 7-15.
25. Papp KA, Tyring S, Lahfa M, et al. A global phase III randomized controlled trial of etanercept in psoriasis: Safety, efficacy and effect of dose reduction. Br J Dermatol 2005; 152: 1304-1312.
26. Perlmutter A, Cather J, Franks B, et al. Alefacept revisited: Our 3-year clinical experience in 200 patients with chronic plaque psoriasis. J Am Acad Dermatol 2008; 58: 116-124.
27. Romero-Mate A, Garcia-Donoso C, Cordoba-Guijarro S. Efficacy and safety of etanercept in psoriasis/psoriatic arthritis: An updated review. Am J Clin Dermatol 2007; 8: 143-155.
28. Saurat JH, Stingl G, Dubertret L, et al. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). Br J Dermatol 2008; 158: 558 -5 -66.
29. Selenko-Gebauer N, Karlhofer F, Stingl G. Efalizumab in routine use: A clinical experience. Br J Dermatol 2007; 156(Suppl. 2): 1-6.
30. Tyring S, Gordon KB, Poulin Y, et al. Long-term safety and efficacy of 50.mg of etanercept twice weekly in patients with psoriasis. Arch Dermatol 2007; 143: 719-726.
31. Cort DH, Schleider NR, Moskowitz RS, et al. Retrospective analysis of a modified Goeckerman regimen for the treatment of psoriasis. Cutis 1980; 25: 201-203.
32. DesGroseilliers JP, Cullen AE, Rouleau GA. Ambulatory Goeckerman treatment of psoriasis: Experience with 200 patients. Can Med Assoc J 1981; 124: 1018-1020.
33. Menter A, Cram DL. The Goeckerman regimen in two psoriasis day care centres. J Am Acad Dermatol 1983; 9: 59-65.
34. Gottlieb AB, Evans R, Li S, et al. Infliximab induction therapy for patients with severe plaque-type psoriasis: A randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol 2004; 51: 534-542.
35. Gottlieb AB, Hamilton T, Caro I, et al. Long-term continuous efalizumab therapy in patients with moderate to severe chronic plaque psoriasis: updated results from an ongoing trial. J Am Acad Dermatol 2006; 54: S154-S163.
36. Langley RG, Ho V, Lynde C, et al. Recommendations for incorporating biologicals into management of moderate to severe plaque psoriasis: individualized patient approaches. J Cutan Med Surg 2006; 9(Suppl. 1): 18-25.
37. Sauder DN, Mamelak AJ. Understanding the new clinical landscape for psoriasis: A comparative review of biologics. J Cutan Med Surg 2004; 8: 205-212.
38. Menter A, Leonardi CL, Sterry W, et al. Long-term management of plaque psoriasis with continuous efalizumab therapy. J Am Acad Dermatol 2006; 54: S182-S188.
39. Golda N, Benham SM, Koo J. Rebound of psoriasis during treatment with efalizumab. J Drugs Dermatol 2006; 5: 63-65.
40. Pittelkow MR, Perry HO, Muller SA, Maughan WZ, O'brien PC. Skin cancer in patients with psoriasis treated with coal tar: A 25 year follow-up study. Arch dermatol 1981; 117: 465-468.
41. Fiala Z, Borska L, Pastorkova A, et al. Genotoxic effect of Goeckerman regimen of psoriasis. Arch Dermatol Res 2006; 298: 243-251.
42. Mukhtar HI, Tito BJ Jr, Matgouranis PM, et al. Additive effects of ultraviolet B and crude coal tar on cutaneous carcinogen metabolism: possible relevance to the tumorigenicity of the Goeckerman regimen. J Invest Dermatol 1986; 87: 348-353.
43. Heymann WR. Side effects of the biologics. J Am Acad Dermatol 2005; 53: 692-693.
44. Sichletidis L, Settas L, Spyratos D, et al. Tuberculosis in patients receiving anti-TNF agents despite chemoprophylaxis. Int J Tuberc Lung Dis 2006; 10: 1127-1132.
45. Debandt M, Vittecoq O, Descamps V, et al. Anti-TNF-alpha-induced systemic lupus syndrome. Clin Rheumatol 2003; 22: 56-61.
46. Desai SB, Furst DE. Problems encountered during anti-tumour necrosis factor therapy. Best Pract Res Clin Rheumatol 2006; 20: 757-790.
47. Boehncke WH, Prinz J, Gottlieb AB. Biologic therapies for psoriasis. A systematic review. J Rheumatol 2006; 33: 1447-1451.
48. Guenther L, Langley RG, Shear NH, et al. Integrating biologic agents into management of moderate-to-severe psoriasis: A consensus of the Canadian Psoriasis Expert Panel February 27, 2004. J Cutan Med Surg 2004; 8: 321-337.
49. Bos WE, Thio HB, Neumann HA, et al. [New systemic treatments for psoriasis: Etanercept, infliximab, adalimumab, efalizumab and alefacept]. Ned Tijdschr Geneeskd 2006; 150: 1065-1070.
50. Andrys C, Borska L, Pohl D, et al. Angiogenic activity in patients with psoriasis is significantly decreased by Goeckerman's therapy. Arch Dermatol Res 2007; 298: 479-83.
51. Papp KA, Miller B, Gordon KB, et al. Efalizumab retreatment in patients with moderate to severe chronic plaque psoriasis. J Am Acad Dermatol 2006; 54: S164-S170.
52. Rich SJ. Considerations for assessing the cost of biologic agents in the treatment of psoriasis. J Manag Care Pharm 2004; 10: S38-S41.
53. Feldman SR. Where has Goeckerman treatment gone? J Dermatol Treat 2005; 16: 73-74.